Amended Quarterly Report (10-q/a)
March 18 2019 - 6:11AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q/A
Amendment
No. 3
[X]
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For
the Quarterly Period Ended March 31, 2017
[ ]
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For
the Transition Period from ____________ to ____________
Commission
File Number: 000-33167
KIWA
BIO-TECH PRODUCTS GROUP CORPORATION
(Exact
name of registrant as specified in its charter)
Nevada
|
|
77-0632186
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(I.R.S.
Employer
Identification
No.)
|
|
|
|
3200
Guasti Road, Suite #100,
Ontario,
California
|
|
91761
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(909)
456-8828
(Registrant’s
telephone number, including area code)
|
310
N. Indian Hill Blvd., #702
Claremont,
California 91711
|
|
|
(Former
address)
|
|
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer [ ]
|
Accelerated
filer [ ]
|
|
|
Non-accelerated
filer [ ]
|
Smaller
reporting company [X]
|
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No
[X]
There
were 16,885,260 shares of the issuer’s common stock outstanding as of March 14, 2019.
Explanatory
Note
The
purpose of this Amendment No. 3 to Kiwa Bio-Tech Products Group Corporation’s Quarterly Report on Form 10-Q for the quarter
ending March 31, 2017 (the “Form 10-Q”), as filed with the Securities and Exchange Commission on March 15, 2019, is
to furnish Exhibits 101 to the Form 10-Q in accordance with Rule 201(c) and Rule 405 of Regulation S-T. Exhibits 101 provide the
financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language). This Amendment
No. 3 to the Form 10-Q also updates the Exhibit Index to reflect the furnishing of Exhibits 101.
No
other changes have been made to the Form 10-Q. This Amendment No. 3 to the Form 10-Q continues to speak as of the original filing
date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify
or update in any way the disclosures made in the original Form 10-Q.
Item
6. Exhibits.
*
|
Filed
as an exhibit to the amended Form 10-Q for the quarter ended March 31, 2017, filed March
15, 2019.
|
|
|
X
|
Filed
herewith
|
|
|
†
|
In
accordance with SEC rules, this interactive data file is deemed “furnished” and not “filed” for purposes
of Sections 11 or 12 of the Securities Act of 1933 and Section 18 of the Securities and Exchange Act of 1934, and otherwise
is not subject to liability under those sections or acts.
|
SIGNATURES
In
accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
KIWA
BIO-TECH PRODUCTS GROUP CORPORATION
|
|
|
|
March
15, 2019
|
By:
|
/s/
Yvonne Wang
|
|
|
Yvonne
Wang, Interim Chief Executive Officer and Interim Chief Financial Officer
|